GT-2203
chemical compound
GT-2203, also known as VUF-5296, (1R,2R)-cyclopropylhistamine, or (1R,2R)-trans-2-(1H-imidazol-4-yl)cyclopropylamine, is a histamine H3 receptor agonist which was under development for the treatment of insomnia and anxiety disorders but was never marketed. Its route of administration was unspecified.
Pharmacology
The drug is a synthetic derivative of the neurotransmitter histamine. The other enantiomer, (1S,2S)-cyclopropylhistamine (VUF-5297), is about 10-fold more potent than GT-2203 as a histamine H3 receptor agonist. Both enantiomers are partial agonists of the receptor and both enantiomers show additional weak activity at the histamine H1 and H2 receptors.
History
GT-2203 was under development by Gliatech. It reached the preclinical research stage of development for insomnia and anxiety disorders prior to the discontinuation of its development in 2004. The drug was first described in the scientific literature by 1997. Aside from immethridine (BP-1-5375), GT-2203 is the only other selective histamine H3 receptor agonist to have been developed for potential pharmaceutical use.
“GT-2203” enters the record as chemical compound. Crown Archives preserves that source wording while asking what GT-2203, chemical and compound can confirm, complicate or overturn.
Why this record matters
“GT-2203” is worth following because a concise public description often conceals a longer documentary argument. Here, GT-2203, chemical and compound provides the most credible route into that argument.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Oct 20, 2025. The linked authority identifier is Q136743802. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2004 and 1997.
Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “GT-2203”, its source revision and the description used here.
- Expand the search: follow GT-2203 primary sources, GT-2203 archive and GT-2203 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “GT-2203”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “GT-2203” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.